Efficacity Study With the Protégé EverFlex Stent in Popliteal Lesions

Peripheral Arterial Disease Clinical Trial

— DUR-POP  

Official title:

DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01412450
• Other study ID #: FMRP-100702
• Status: Completed
• Phase: Phase 4
• First received: July 2, 2010
• Last updated: September 30, 2013
• Start date: July 2010
• Est. completion date: August 2012

Study information

• Verified date: September 2013
• Source: Flanders Medical Research Program
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

This study will assess the results up to 12 months with the Protégé EverFlex stent (ev3) in patients presenting with a narrowing or blocking at the level of the knee artery, which leads to a limited walking distance, rest pain or non-healing ulcers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

General Inclusion criteria

• De novo, restenotic or reoccluded lesion located in the popliteal artery, with or without superficial femoral artery involvement

• Patient presenting a score from 2 to 5 following Rutherford classification

• Patient is willing to comply with specified follow-up evaluations at the specified times

• Patient is >18 years old

• Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study

• Prior to enrollment, the guidewire has crossed target lesion

• Patient is eligible for treatment with the self-expanding nitinol EverFlex (ev3) stent

Angiographic Inclusion Criteria

• The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation

• The target lesion, visually estimated, has a maximal length of 14 cm and can be categorized as either a type A or B lesions according the TASC II guidelines

• Target vessel diameter visually estimated is >3.5mm and <7.5 mm

• There is angiographic evidence of at least one-vessel-runoff to the foot

Exclusion Criteria:

• Presence of another stent in the target vessel that was placed during a previous procedure

• Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis

• Previous by-pass surgery in the same limb

• Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated

• Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site

• Perforation at the angioplasty site evidenced by extravasation of contrast medium

• Patients with known hypersensitivity to nickel-titanium

• Patients with uncorrected bleeding disorders

• Aneurysm located at the level of the SFA and/or popliteal artery

• Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding

• Life expectancy of less than twelve months

• Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis > 30% or ipsilateral iliac treatment conducted after the target lesion procedure

• Use of thrombectomy, artherectomy or laser devices during procedure

• Any patient considered to be hemodynamically unstable at onset of procedure

• Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• nitinol stent
implantation of one Protégé EverFlex stent

Locations

Country	Name	City	State
Belgium	Imeldaziekenhuis	Bonheiden	Antwerp
Belgium	A.Z. Sint-Blasius	Dendermonde	East-Flanders
Belgium	University Hospital Antwerp	Edegem	Antwerp
Belgium	Heilig-Hart Ziekenhuis	Tienen	Flemish Brabant

Sponsors (1)

Lead Sponsor	Collaborator
Flanders Medical Research Program

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	primary patency	primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR within 12 months	12 months post-procedure	No
Secondary	Technical success	Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging	1 day post-procedure	No
Secondary	Primary patency rate at 6-, 12-month follow-up.	Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without prior TLR are defined as being primary patent.	6-, 12-month follow-up	No
Secondary	Clinical success	Clinical success at follow-up is defined as an improvement of Rutherford classification at 6-, 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification.	6-, 12-month follow-up	No
Secondary	tent fracture rate at 12-month follow-up	Determined according the following classification on x-ray: Class 0 (no strut factures); Class I (single tine fracture); Class II (multiple tine factures); Class III (Stent fracture(s) with preserved alignment of the components); Class IV (Stent fracture(s) with mal-alignment of the components); Class V (Stent fracture(s) in a trans-axial spiral configuration)	12-month follow-up	No
Secondary	Serious adverse events	Defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.	1 year	No